Abstract The objective of this article is to review genotoxicological profile of the major selective estrogen receptor modulators, including clomiphene, tamoxifen, toremifene, raloxifene. These drugs have been used for infertility treatment and breast cancer prevention in high risk-women. However, some studies reported that especially tamoxifen is a genotoxic agent and is related with endometrial cancer. Our review indicate that clomiphene and tamoxifen were found as genotoxic agent in majority of the tests. However published reports showed that toremifene is a weakly genotoxic agent. The genotoxic effects of raloxifene are still poorly known. Further genotoxicity studies should be conducted especially for raloxifene.
Introduction
Estrogens are a class of sex steroid hormones that are synthesized from cholesterol and are secreted primarily by the ovaries, with contributions from placenta, adipose tissue, and adrenal glands (Lewis and Craig Jordan 2005) . They have a number of important physiological effects on hormone-dependent reproductive tissues (Robertson 2004) . They control the growth of breast epithelial tissue, regulate the menstrual cycle by promoting endometrial proliferation in the uterus, and regulate circulating cholesterol levels, thereby providing a protective effect on the cardiovascular system (Robertson 2004; Jordan 1996) . The biological role of estrogen is mediated through high-affinity binding to the estrogen receptor (ER) (Robertson 2004; Cavailles 2002) . Exposure to high level of estrogens, especially due to in vitro fertilization, can cause different tumours. For example, breast tumours that express the ER are stimulated by estrogen (Lippman et al. 1977 ) and anti-estrogen therapy has thus become an established treatment for ER-positive breast cancer (Robertson 2004) . Estrogens in general showed their genotoxicity by different mechanisms; (a) formation of apurinic sites in DNA (Cavalieri et al. 2002) , (b) genaration of reactive oxygen species (Roy and Liehr 1999) , (c) other undetermined, especially epigenetic mechanisms (Dipple et al. 1984) .
Selective estrogen receptor modulators (SERMs) are compounds that act as estrogen agonists on selected targets while being estrogen antagonists on others. The main roles of SERMs are estrogen agonist activity on bone metabolism, several functions of the cardiovascular system and estrogen antagonism in the breast and uterus (Halbreich and Kahn 2000) . Several compounds that exhibit a SERM property are currently available for clinical use. Among them clomiphene, tamoxifen, toremifene, raloxifene are used most frequently (Goldstein et al. 2000) . Tamoxifen is the first approved drug by the international authorities (FDA, WHO, etc.) to prevent malign breast carcinoma. However, studies have been conducted that long-term use of tamoxifen may result in a two to sevenfold increase in the risk of developing endometrial cancer (Singh et al. 2007) .
The aim of the present review was to evaluate genotoxicological profile of these SERMs. Genotoxicity is a broader term that refers to the ability to interact with DNA and/or the cellular apparatus that regulates the accuracy of the genome, such as the spindle apparatus and topoisomerase enzymes (Maurici et al.) . In general genotoxic agents can lead to cancer. Hence, evaluation of the possible genotoxicity of a chemical is an important issue.
Selective estrogen receptor modulators (SERMs)

Clomiphene
Clomiphene is a non steroidal, ovulation stimulant (Csemiczky et al. 2002) and SERM (Fig. 1) . It is a synthetic hormone that deceives the hypothalamus into perception that body's estrogen level is too low. In return, the hypothalamus releases GnRH (gonadotropin-releasing hormone), which activates the pituitary gland to release a sufficient amount of follicle stimulating hormone (FSH). Then an increased amount of FSH stimulates development of follicles, ultimately resulting in ovulation (Randal and Templeton 1991; Martikainen et al. 2006; Chaman and Asmatullah 2011) . Some authors have reported that treatment with clomiphene is related with various malignancies including endometrial and ovarian cancers (Derman and Adashi 1994; Althuis et al. 2005; Lerner-Geva et al. 2006; Calderon-Margalit et al. 2009; Jensen et al. 2009 ).
Genotoxicity
Genotoxic effects of clomiphene have been reported in different test systems by several authors. Zambrano et al. (1982) reported that clomiphene showed no increase in frequency of either chromosomal aberrations or polychromatic erythrocytes in mouse bone marrow. Ohnishi et al. (1986) reported that clomid which contains clomiphene, induced DNA-strand breaks and SOS responses such as mutation and expression of the umuC? gene in E. coli (Ohnishi et al. 1986 ). Styles et al. (1997) investigated the clastogenic and aneugenic effects of clomiphene in human lymphoblastoid cell line (MCL5). Different authors have reported that there was an increase in micronuclei and chromosomal aberrations (aneuploidy) in cells treated with clomiphene. Arriaga-Alba et al. (1996) stated that clomiphene induced frameshift mutations in the Salmonella typhimurium TA1538, TA97 and TA100 strains in vitro by using metabolic S9 activation. However, it did not induce base pair substitution mutations. Clomiphene induced genolethal DNA damages in Escherichia coli PolA-/ PolA? in the pre-incubation method with S9 and in the disk diffusion method without S9 (Arriaga-Alba et al. 1996) . London et al. (2000) reported that clomiphene decreased the number of ovulated oocytes and significantly (P \ .05) increased the hyperploidy at 100 mg/kg in vivo. Similarly, in vitro 5.0 lg/mL concentration of clomiphene significantly (P \ .05) increased the level of hyperploidy and reduced the proportion of metaphase I oocytes in mouse in vitro (London et al. 2000) . Duran et al. (2006) investigated the potential genotoxicity of clomiphene in rat reticulocytes by micronucleus assay. 0.16, 0.32 and 0.64 mg/kg concentrations of clomiphene were administrated to rats intraperitoneally for 5 days. Authors have observed that clomiphene showed a dose-dependent increase in genomic instability and micronucleus frequency in bone marrow stem cells of rats (Duran et al. 2006) . Hastwell et al. (2009) reported that clomiphene has no genotoxic affect on the human lymphoblastoid TK6 cell line using the GADD45a-GFP ''Green Screen HC'' genotoxicity assay. Yılmaz et al. (2014) reported that 0.4, 0.8, 1.6 and 3.2 lg/mL concentrations of clomiphene caused significant increase in chromosomal aberrations, micronucleus frequency and DNA damage (comet assay) in human lymphocytes. It also caused cell cycle delay by decreasing the mitotic index. In this work authors have also reported that clomiphene did cause neither base-pair substitutions nor frame-shift mutations in S. typhimurium TA98 and TA100 strains (Yılmaz et al. 2014 ). In our laboratory we have also worked on the SCE induction of clomiphene in human lymphocytes (Unpublished report). Our results support most of the previous findings since clomiphene caused a significant increase in sister chromatid exchanges in human lymphocytes (Table 1) .
Tamoxifen
Tamoxifen is a nonsteroidal antiestrogenic agent used for the breast cancer therapy for over 30 years ( Fig. 2) . It is a SERM and primarily binds to ERs to inhibit the growth of malignant cell (development of malignancy). Some authors have reported that tamoxifen increases the risk for endometrial cancer (Magriples et al. 1993; Seoud et al. 1993; Fisher et al. 1994; van Leeuwen et al. 1994; Cook et al. 1995; Cuenca et al. 1996; Curtis et al. 1996) while it is a clearly beneficial agent for the breast cancer prevention. Furthermore, tamoxifen is a potent hepatocarcinogen in rats (Greaves et al. 1993; White 1999) . Tamoxifen-DNA adducts (Philips et al. 1994; Phillips 2001; Beland et al. 1999; Gamboa da Costa et al. 2001; Carthew et al. 2001) can cause hepatic tumors. It has also been demonstrated that rat and human liver microsomal fractions metabolize tamoxifen to reactive intermediates that bind covalently protein and DNA (Mani and Kupfer 1991; Pathak and Bodell 1994; Carmichael et al. 1996) .
Genotoxicity
Genotoxicity of tamoxifen has been investigated by different test systems. Tucker et al. (1984) observed that tamoxifen is not mutagenic in the AMES test. Tamoxifen induced a significant increase in micronucleus formation in a dose dependent manner in cultures of MCL-5 cells, a human cell line that expresses five different human cytochrome P450 isoenzymes, as well as epoxide hydrolase. Exposure of rat hepatocytes to tamoxifen in vitro, resulted in induction of unscheduled DNA synthesis, when preparations from rats which had been pretreated with tamoxifen in vivo were used (White et al. 1992) . Wilson et al. (1995) reported that 50 lM tamoxifen decreased human lymphocyte proliferation but it did not exert a genotoxic activity. Tamoxifen induced aneuploidy was observed by Sargent et al. (1994 Sargent et al. ( , 1996 in Sprague-Dawley rats. Vijayalaxmi and Rai (1996) studied the genotoxic effects of tamoxifen citrate using a mouse bone marrow chromosome aberration assay and micronucleus test. 0.1, 0.2, 0.4 and 0.8 mg/kg/day dose were administrated to the mice for 10 days. A statistically significant chromosomal aberration and MN induced by tamoxifen revealed its clastogenic potency. Carmichael et al. (1996) reported that tamoxifen did not cause DNA adducts in human endometrial cells. The authors concluded also that genotoxic events observed with tamoxifen in the rat may not apply to the human endometrium. The clastogenicity of tamoxifen was tested in six human lymphoblastoid cell lines each expressing increased monooxygenase activity associated with a specific transfected human cytochrome P450 cDNA (CYP1A1, CYP1A2, CYP2D6, CYP2E1 or CYP3A4). Dose-related increases in micronuclei were observed when cells expressing 2E1, 3A4, 2D6 or MCL-5 cells were exposed to tamoxifen (Styles et al. 1997) . The cytotoxicity of the tamoxifen has been investigated in the RPE cell line D407 and pig RPE cell culture using the WST-1 test, which is an assay of cell proliferation and viability (Mannerström et al. 2002) . Tamoxifen was found cytotoxic in this test system. Chronic treatments with tamoxifen citrate were performed with 3-day-old larvae of the standard and high bioactivation crosses of the wing spot test in Drosophila at concentrations of 0.66, 1.66 and 3.33 mM by HeresPulido et al. (2004) . Somatic spots on normal wings from marker heterozygous flies and on serrate wings from balancer heterozygous flies were scored to determine mutation and recombination events in somatic cells. The results showed genotoxic effects of tamoxifen at 1.66 and 3.33 mM in the ST cross only and without a clear dose-response effect. This suggests a weak genotoxicity of this anti-estrogen. Al-Jassabi et al.
(2011) investigated the genotoxicity of drug tamoxifen in Balb/c male mice to induce oxidative DNA damage through the formation of 8-hydroxydeoxyguanosine using HPLC with electrochemical detection. Authors have reported that tamoxifen initiates reactive oxygen species formation followed by damage of DNA and other cellular compartments. Rodrigues et al. (2012) studied the tamoxifen induced micronuclei in female Wistar-Hannover rats. The results indicate that tamoxifen reduced formation of micronuclated polychromatic erythrocytes (Table 2) .
Toremifene
Toremifene is a nonsteroidal estrogen antagonist and has been used for over 20 years (Fig. 3) . The drug is (Wiseman and Goa 1997) . Tamoxifen's antitumor activity is generally postulated also for toremifene. Stimulation of the transforming growth factor b secretion, inhibition of TGF-a and epidermal growth factor secretion, interaction with antiestrogen binding sites, inhibition of protein kinase C activity and binding to calmodulin may be the possible mechanisms of antitumour activity of this drug (Wiseman and Goa 1997; Buckley and Goa 1989; Jordan 1993 ). Toremifene has not been linked to an increase in endometrial cancer (Holli et al. 1998) and is available as an alternative to tamoxifen for the treatment of metastatic breast cancer (Buzdar and Hortobagyi 1998). Styles et al. (1997) investigated the clastogenic and aneugenic effects of toremifene and 4-hydroxytoremifene in the human lymphoblastoid cell line (MCL5). With MCL-5 cells there was an increase in micronuclei formation with 4-hydroxytoremifene. The incidence of cells with numerical chromosomal aberrations (aneuploidy) and structural abnormalities (excluding gaps) was increased in cells treated with toremifene. Williams et al. (1998) evaluated toremifene genotoxicity in three in vitro assays: reversion of bacterial point mutations, unscheduled DNA synthesis in cultured hepatocytes from two rat strains and cytogenetics of human lymphocytes and in one in vivo assay: the mouse erythrocyte micronucleus assay. 100-250 mg/mL concentrations were used depending on the system. To test for chromosome damage in vivo, mice were administered up to 2 g/kg toremifene once by gavage, for 3 days. Toremifene lacked genotoxicity or myelotoxicity detectable by any of the above assays. Okuboa et al. (1998) reported that toremifene and N-desmethyltoremifene did not cause damage in pUC18 plasmid DNA. The cytotoxicity of toremifene has been investigated in RPE cell line D407 and the pig RPE cell culture using the WST-1 test (Mannerström et al. 2002) . Toremifene was found cytotoxic in these test systems. Umemoto et al. (2006) studied the capability of forming DNA adducts by toremifene in the leukocytes of patients. Leukocytes were collected from 27 breast cancer patients taking toremifene (40 mg/day for 25 patients, Williams, and Jeffrey (1997) , White (1999) , Rajaniemi et al. (1998a, b) , Hellmann-Blumberg et al. (2000) pUC18 plasmid DNA DNA damage - Okuboa et al. (1998) RPE cell line D407, pig RPE cell culture WST-1 test ? Mannerström et al. (2002) ?: Positive, -: Negative Cytotechnology (2014) 66:533-541 537 80 mg/day for one patient, and 120 mg/day for one patient) and 20 untreated breast cancer patients. No DNA adducts were detected in the leukocytes of either toremifene-treated or non-treated patients by 32 Ppostlabeling/high-performance liquid chromatography. Furthermore, DNA adduct formation was low or negative in the experiments of Williams and Jeffrey (1997) , White (1999) , Rajaniemi et al. (1998a, b) , Hellmann-Blumberg et al. (2000) (Table 3 ).
Genotoxicity
Raloxifene
Raloxifene, was initially approved for the treatment and prevention of osteoporosis in postmenopausal woman (Fig. 4) . Raloxifene inhibits the estrogen-induced breast tissue proliferation and seems to prevent breast cancer in high-risk women (Liu et al. 2003) . Unlike tamoxifen, it is not reacting with DNA due to absence of ethyl moiety (Cummings et al. 1999) . Goldstein et al. (2000) reported that raloxifene was not increasing the incidence of endometrial cancer. Martino et al. (2005) studied the safety of raloxifene over 8 years in a clinical trial setting. The authors reported that 8-year data support the known clinical safety profile of raloxifene.
Genotoxicity
The genotoxicity of the raloxifene is poorly investigated. Only a few studies have been conducted. Rajaniemi et al. (1998a, b) reported that raloxifene did not cause DNA adducts in rat liver. Rodrigues et al. (2012) studied the micronucleus induction by raloxifene in female Wistar-Hannover rats (Table 4) . The authors have reported that raloxifene did not cause micronuclei induction, furthermore it decreased the micronuclated polychromatic erythrocytes in rats.
Conclusion
Selective estrogen receptor modulators are very effective drugs for the treatment and prevention of the breast cancer, and also treatment of infertility. Tamoxifen is an important drug for the prevention of breast cancer, however long term use can cause side effects especially endometrial cancer. Clomiphene is the leading drug for the treatment of infertility. But genotoxic profiles of clomiphene should be taken into consideration. Toremifene is an estrogen antagonist and unlike for tamoxifen experimental data showed that it did not cause endometrial cancer. Raloxifene is currently used for the treatment and prevention of post-menopausal osteoporosis and is also used for breast cancer prevention in high-risk women. Information on the genotoxicity of raloxifene is scanty, so detailed works should be conducted using different test systems. Our review indicates that tamoxifen and clomiphene are more genotoxic agents than raloxifene and toremifene. 
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